Serotonin–norepinephrine–dopamine releasing agent

Type of drug

A serotonin–norepinephrine–dopamine releasing agent (SNDRA), also known as a triple releasing agent (TRA), is a type of drug which induces the release of serotonin, norepinephrine/epinephrine, and dopamine in the brain and body. SNDRAs produce euphoriant, entactogen, and psychostimulant effects, and are almost exclusively encountered as recreational drugs.

A closely related type of drug is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI).

Stahl uses the term "Trimonoaminergic Modulators" (TMM) in his work.

Examples of SNDRAs

Examples of SNDRAs include specific amphetamines such as MDMA, MDA, 4-methylamphetamine, methamphetamine (in high doses), certain substituted benzofurans such as 5-APB and 6-APB, naphthylisopropylamine; cathinones such as mephedrone and methylone; tryptamines such as αMT and αET; along with agents of other chemical classes such as 4,4'-DMAR, and 5-IAI.[1] αET and αMT are of special notability among SNDRAs in that those tryptamines were once used as pharmaceutical drugs, specifically as antidepressants, but were withdrawn shortly after introduction in the 1960s due to problems with toxicity and recreational use.[2][3][4] Such tryptamines were originally thought to act as monoamine oxidase inhibitors (MAOIs) before the signature monoamine-releasing actions were elucidated.[3][4] Many years after being withdrawn, αET was also determined to produce serotonergic neurotoxicity, similarly to MDMA and various other SNDRAs; the same is very likely true for αMT as well, although it has not specifically been assessed.[5]

See also

References

  1. ^ Bruce E. Blough, Richard Rothman, Antonio Landavazo, Kevin M. Page, Ann Marie Decker. Phenylmorpholines and analogues thereof. US Patent 2013/0203752
  2. ^ Donald G. Barceloux (20 March 2012). Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. John Wiley & Sons. pp. 196–. ISBN 978-0-471-72760-6.
  3. ^ a b Leslie Iversen (11 November 2013). Handbook of Psychopharmacology: Volume 14 Affective Disorders: Drug Actions in Animals and Man. Springer Science & Business Media. pp. 132–. ISBN 978-1-4613-4045-4.
  4. ^ a b Biological Research on Addiction: Comprehensive Addictive Behaviors and Disorders. Academic Press. 17 May 2013. pp. 632–. ISBN 978-0-12-398360-2.
  5. ^ Huang, Xuemei; Johnson, Michael P.; Nichols, David E. (1991). "Reduction in brain serotonin markers by α-ethyltryptamine (Monase)". European Journal of Pharmacology. 200 (1): 187–190. doi:10.1016/0014-2999(91)90686-K. ISSN 0014-2999. PMID 1722753.

External links

  • Media related to Serotonin-norepinephrine-dopamine releasing agents at Wikimedia Commons
  • v
  • t
  • e
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
See also: Receptor/signaling modulators • Monoamine reuptake inhibitors • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
  • v
  • t
  • e
TAAR1
Agonists
Endogenous
Synthetic
Neutral antagonists
  •  
Inverse agonists
TAAR2
Agonists
 
Neutral antagonists
  •  
TAAR5
Agonists
Neutral antagonists
  •  
Inverse agonists
References for all endogenous human TAAR1 ligands are provided at List of trace amines


References for synthetic TAAR1 agonists can be found at TAAR1 or in the associated compound articles. For TAAR2 and TAAR5 agonists and inverse agonists, see TAAR for references.


See also: Receptor/signaling modulators


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e